Overview
Augustine Therapeutics focuses on therapeutic approaches to diseases affecting the nervous system and muscles, a field with significant unmet medical need and growing scientific understanding of underlying mechanisms. The company was co-founded by Ludo Van Den Bosch, Bart De Strooper, and Joris De Wit, researchers with strong academic credentials in neuroscience.
The EUR 77.7M Series A, raised in H1 2025, is one of the larger biotech rounds in recent Belgian history and provides substantial capital for clinical development. PMV, the Flemish public investment vehicle, is among the backers, reflecting the strategic interest in building a durable life sciences sector in Flanders.
Funding & milestones
1 events found for Augustine Therapeutics · 2025
Series AVenture / equityDetailsEUR 77.7M
Reported amount EUR 77,700,000
Source not attached to this recordDeal record
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Profile narrative
- Series A: EUR 77.7M (H1 2025)
Key people
Backers
PMV (ParticipatieMaatschappij Vlaanderen)
Flemish government investment arm with a EUR 1.9B portfolio, backing tech and biotech companies with tickets up to EUR 20M.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.